Although the emergence of tyrosine kinase receptor inhibitors (TKIs), such as sunitinib and cabozantinib, has largely improved the prognosis of RCC patients, the inevitable development of resistance to these inhibitors has made it urgent to explore novel treatment strategies for RCC [3, 4]. Here, NTRK1 is linked to renal cell carcinoma.